Influence of the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, rosiglitazone and antagonist, biphenol-a-diglicydyl ether (BADGE) on the course of inflammation in the experimental model of colitis in rats

Journal of Physiology and Pharmacology

Volumn 61, Issue 6, 2010, Pages 683-693

  Dworzanski, T ^a   Celinski, K ^a   Korolczuk, A ^a   Slomka, M ^a   Radej, S ^a   Czechowska, G ^a   Madro, A ^a   Cichoz Lach, H ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Biphenol a diglicydyl ether (BADGE); Interleukin 1 ; Peroxisome proliferator activated receptor gamma; Rosiglitazone; Trinitrobenzene sulfonate (TNBS); Tumor necrosis factor

Indexed keywords

BIPHENOL A DIGLICYDYL ETHER; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FOOD INTAKE; LYMPHOCYTE; NONHUMAN; PLASMA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; COLITIS; CYTOKINES; EPOXY COMPOUNDS; INTESTINE, LARGE; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 79251499729     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Sokolowska M, Kowalski ML, Pawliczak R. Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) and their role in immunoregulation and inflammation control. Post Hig Med Dosw 2005; 59: 472-484.
2. Celinski K, Dworzanski T, Prozorow-Krol B, Korolczuk A. The role of PPAR-γ receptors in gastrointestinal inflammation diseases. Gastroenterol Pol 2009; 16: 51-56.
3. Celinski K, Madro A, Prozorow-Krol B, et al. Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR- γ)-specific agonist, as a modulator in experimental acute pancreatitis. Med Sci Monit 2009; 15: 21-29.
4. Baranowski M, Blachnio-Zabielska A, Gorski J. Peroxisome proliferator-activated receptor alpha activation induces unfavourable changes in fatty acid composition of myocardial phospholipids. J Physiol Pharmacol 2009; 60: 13-20.
5. Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Gorski J. Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver. J Physiol Pharmacol 2009; 60: 99-106.
6. Pontsler AV, St Hilaire A, Marathe GK, Zimmerman GA, McIntyre TM. Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator-activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem 2002; 277: 13029-13036.
7. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator- activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.
8. Chinetti G, Lestavel S, Fruchart JC, Clavey V, Staels B. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res 2003; 92: 212-217.
9. Wang AC, Dai X, Luu B, Conrad DJ. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 2001; 24: 688-693.
10. Li M, Pascual G, Glass CK. Peroxisome proliferator- activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 2000; 20: 4699-4707.
11. Konturek PC, Dembinski A, Warzecha Z, et al. Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis. World J Gastroenterol 2005; 11: 6322-6329.
12. Konturek PC, Brzozowski T, Engel M, et al. Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves. J Physiol Pharmacol 2009; 60(2): 41-47.
13. Kiec-Wilk B, Dembinska-Kiec A, Olszanecka A, Bodzioch M, Kawecka-Jaszcz K. The selected pathophysiological aspects of PPARs activation. J Physiol Pharmacol 2005; 56: 149-162.
14. Ptak-Belowska A, Pawlik MW, Krzysiek-Maczka G, Brzozowski T, Pawlik W.W. Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated receptor gamma agonist triggers cell survival pathways. J Physiol Pharmacol 2007; 58(4): 793-801.
15. Chawla A, Schwarz EJ, Dimaculangan DD, Lazer MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135: 798-800.
16. Fajas L, Auboeuf D, Raspe E, et al. The organization, promotor analysis and expression of the human PPAR gamma gen. J Biol Chem 1997; 272: 18779-18789.
17. Fajas L, Fruchard JC, Auwerx J. PPARgamma3 mRNA: a distinct PPAR gamma mRNA subtype transcribed from an independent promotor. FEBS Lett 1998; 438: 55-60.
18. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor- gamma. J Exp Med 2005; 201: 1205-1215.
19. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999; 104: 383-389.
20. Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 2008; 10: 617-625.
21. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235-238.
22. Joosen AM, Bakker AH, Kersten S, Westerterp KR. The PPARgamma ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARgamma in the subcutaneous adipose tissue. Br J Nutr 2008; 99: 487-493.
23. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005; 102: 7671-7676.
24. Ten T, Hove A, Corbaz H, et al. Blockade of endogenous IL- 18 ameliorates TNBS-induced colitis by decreasing local TNF-α production. Gastroenterology 2001; 121: 1372-1379.
25. Nakai M, Sudo K, Yamada Y, et al. The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. Digest Dis Sci 2005; 50: 1669-1676.
26. Hollenbach E, Vieth M, Roessner A, et al. Inhibition of RICK/nuclear factor-kB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem 2005; 280: 14981-14988.
27. Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon de la Lastra C. Rosiglitazone, a PPARγ ligand, modulates signal transduction pathways during the development of acute TNBS- induced colitis in rats. Eur J Pharmacol 2007; 562: 247-258.
28. Wright H, Clish C, Mikamii T, et al. A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits dipocyte differentiation. J Biol Chem 2000; 275: 1873-1877.
29. Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon de la Lastra C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 2005; 69: 1733-1744.
30. Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink RP, Plat J. The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol 2007; 27: 275-283.
31. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001; 193: 827-838.
32. Saubermann LJ, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002; 8: 330-339.
33. Schaefer KL, Denevich S, Ma C, et al. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 2005; 11: 244-252.
34. Takaki K, Mitsuyama K, Tsuruta O, Toyonaga A, Sata M. Attenuation of experimental colonic injury by thiazolidinedione agents. Inflamm Res 2006; 55: 10-15.
35. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61: 2424-2428.
36. Shan YM, Morimura K, Gonzalez FJ. Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimental induced colitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: 657-666.
37. Yamamoto K, Ninomiya Y, Iseki M, et al. 4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor c agonist alleviates the symptoms of DSS-induced colitis. Biochem Biophys Res Commun 2008; 367: 566-572.